Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Exclusive Content A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthor: Jordan Chussler. First Published: 1/14/2026. 
At a Glance - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors shouldn't dismiss every newly public company; some recently listed stocks may merit a place in buy-and-hold portfolios. SpaceX just announced it is rapidly repositioning 4,400 Starlink satellites into lower Earth orbit. While the official explanation points to safety and debris concerns, the move comes days after China labeled Starlink a national security threat, raising serious questions about what's really happening behind the scenes.
If this escalation in space is an early warning signal, most investors won't react until markets already feel the impact. One analyst has updated his playbook for how to protect capital if geopolitical tensions accelerate. See the full briefing and his 3-step plan here One biotechnology company in the healthcare sector that just went public could be an example of that. Last Year's IPO Success Stories Last year provides a strong reminder that newly public companies shouldn't be automatically dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its IPO. Short-term speculators may have capitalized on its almost 359% gain before 30 days on the Nasdaq, but longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the misconception that IPOs are only high-risk startups. The medical products and services provider, which debuted in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with targeting molecules that seek out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing damage to healthy tissue compared with some conventional therapies. According to industry consultant Grand View Research, the global nuclear medicine market was estimated at nearly $18 billion in 2024 and is forecast to reach almost $35 billion by 2030, implying a compound annual growth rate of 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the dominant regional player. Aktis Oncology's Clinical-Stage Biotechnology Wall Street expects biotech IPOs to rebound in 2026 after funding cuts under the Trump administration notably slowed healthcare-sector listings in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised $318 million in IPO proceeds, giving the firm a market capitalization of about $3.34 billion at listing. According to the company's prospectus, its executive team includes experts in drug development, regulatory approval, and commercialization, with members of management having helped bring 14 currently FDA-approved products to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision oncology drugs that use proprietary technology to target solid tumors while minimizing exposure to healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not deter investor interest: Eli Lilly (NYSE: LLY) anchored the IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares as part of the offering. This follows a 2024 collaboration in which Lilly committed $60 million in cash and an equity investment in Aktis to develop tumor-targeting radiopharmaceuticals, with potential milestone payments exceeding $1 billion. The significance of Eli Lilly's backing should not be understated. At about $1.01 trillion in market cap, Lilly is the largest Big Pharma company by that measure, after net income rose nearly 109% year over year from 2023 to 2024. That momentum is likely to remain in focus when Lilly reports Q4 and full-year 2025 financial results on Feb. 5. Between its equity stake and the recent $100 million purchase of AKTS stock, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
| 
